Drug firm Lupin Ltd on Friday (December 13) announced the acquisition of trademarks for three anti-diabetes brands — Gibtulio, Gibtulio Met, and Ajaduo — from Boehringer Ingelheim International GmbH. The acquisition is expected to bolster Lupin’s diabetes portfolio in India, a critical therapeutic segment for the company.
| Company | Value | Change | %Change |
|---|
Under the terms of the agreement, the trademark rights for these brands will officially transfer to Lupin by March 2025. The company has been co-marketing Gibtulio and Gibtulio Met since 2016 and Ajaduo since 2018 through its partnership with Boehringer Ingelheim India.
Gibtulio (empagliflozin), Gibtulio Met (empagliflozin + metformin) and Ajaduo (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations).
These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease.
Nilesh Gupta, Managing Director, Lupin, said, "Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India."
Rajeev Sibal, President of India Region Formulations, Lupin, said, "The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India."
Shares of Lupin Ltd ended at ₹2,075.75, down by ₹41.35, or 1.95%, on the BSE.